Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

6.8%

5 terminated out of 73 trials

Success Rate

85.3%

-1.3% vs benchmark

Late-Stage Pipeline

21%

15 trials in Phase 3/4

Results Transparency

28%

8 of 29 completed with results

Key Signals

8 with results85% success

Data Visualizations

Phase Distribution

58Total
Not Applicable (31)
Early P 1 (1)
P 1 (2)
P 2 (9)
P 3 (11)
P 4 (4)

Trial Status

Completed29
Unknown14
Recruiting9
Not Yet Recruiting9
Active Not Recruiting5
Terminated5

Trial Success Rate

85.3%

Benchmark: 86.6%

Based on 29 completed trials

Clinical Trials (73)

Showing 20 of 20 trials
NCT06880562Not ApplicableNot Yet RecruitingPrimary

The RESPLASH Study

NCT07833098Phase 2Not Yet Recruiting

A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

NCT05888233Phase 2Completed

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

NCT07790120Phase 3Completed

A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06526858Not ApplicableRecruitingPrimary

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT06216808Not ApplicableActive Not RecruitingPrimary

A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension

NCT06168409Phase 3CompletedPrimary

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

NCT06034743Phase 3Completed

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT07707583Not Yet RecruitingPrimary

Heart Rate Variability and Medication Adherence in Resistant Hypertension

NCT07635914Phase 3Not Yet RecruitingPrimary

A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension

NCT07589881Not ApplicableCompletedPrimary

An Educational Intervention on Medication Adverse Effects in Patients With Resistant Hypertension (HTAR-CSI)

NCT07207226Not ApplicableActive Not RecruitingPrimary

Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension

NCT06344104Phase 3Completed

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06169241Early Phase 1Recruiting

Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients

NCT05464849Completed

Evaluation of Systemic Microvascular Reactivity in Patients With Resistant Hypertension

NCT04388124Phase 2RecruitingPrimary

Endothelin-1 Receptor Blockade in Resistant Hypertension

NCT06829537CompletedPrimary

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

NCT07383220Not ApplicableRecruitingPrimary

Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure

NCT05562934Phase 2CompletedPrimary

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

NCT07232966Phase 3Not Yet RecruitingPrimary

Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

Scroll to load more

Research Network

Activity Timeline